Payment overview · 2025
General Payments
$2,279.18
82 reported records · 20 companies
Healthcare provider profile · identity verified
Gitendra Rajiyah, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · EAST ORANGE, NJ · NPI 1083693196
Verified facts
What the public records show
CMS Open Payments records show Gitendra Rajiyah, MD received $2,279.18 in general payments during 2025 across 82 reported records.
Abbott Laboratories accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 900 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 900 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $355.34 | 15.6% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $352.76 | 15.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $341.59 | 15.0% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $247.15 | 10.8% | 17 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $201.11 | 8.8% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $187.77 | 8.2% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $145.21 | 6.4% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $125.99 | 5.5% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.98 | 1.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.66 | 1.7% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $38.84 | 1.7% | 2 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $38.00 | 1.7% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $33.29 | 1.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.19 | 1.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.11 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.96 | 0.8% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $17.52 | 0.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.13 | 0.8% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $15.46 | 0.7% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$14.12 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,279.18 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $355.34 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $352.76 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $201.11 | 6 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $199.84 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $187.77 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $145.21 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $128.12 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $125.99 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.20 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $47.31 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $38.84 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $33.29 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $10.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $8.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 900 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 254 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 146 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 233 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 172 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
118 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
146 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 67 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
900 | 175 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
87 | 25 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
254 | 65 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
172 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
900 | 175 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1348 | 425 |
| Clopidogrel | Clopidogrel Bisulfate | 935 | 300 |
| Eliquis | Apixaban | 900 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 890 | 307 |
| Metoprolol Succinate | Metoprolol Succinate | 762 | 238 |
| Furosemide | Furosemide | 717 | 203 |
| Carvedilol | Carvedilol | 659 | 185 |
| Metoprolol Tartrate | Metoprolol Tartrate | 543 | 155 |
| Losartan Potassium | Losartan Potassium | 536 | 178 |
| Gabapentin | Gabapentin | 528 | 173 |
| Pantoprazole Sodium | Pantoprazole Sodium | 522 | 156 |
| Metformin Hcl | Metformin Hcl | 456 | 155 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 449 | 154 |
| Hydrochlorothiazide | Hydrochlorothiazide | 434 | 156 |
| Simvastatin | Simvastatin | 365 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 352 | 116 |
| Lisinopril | Lisinopril | 332 | 119 |
| Hydralazine Hcl | Hydralazine Hcl | 313 | 89 |
| Clonidine Hcl | Clonidine Hcl | 290 | 81 |
| Ezetimibe | Ezetimibe | 261 | 95 |
| Entresto | Sacubitril/Valsartan | 254 | 65 |
| Montelukast Sodium | Montelukast Sodium | 239 | 75 |
| Jardiance | Empagliflozin | 233 | 67 |
| Omeprazole | Omeprazole | 222 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 54 |
| Torsemide | Torsemide | 180 | 51 |
| Ozempic | Semaglutide | 172 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 165 | 42 |
| Farxiga | Dapagliflozin Propanediol | 146 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 143 | 47 |
| Trazodone Hcl | Trazodone Hcl | 133 | 29 |
| Spironolactone | Spironolactone | 132 | 44 |
| Potassium Chloride | Potassium Chloride | 129 | 39 |
| Levetiracetam | Levetiracetam | 128 | 28 |
| Allopurinol | Allopurinol | 124 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 122 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 122 | 41 |
| Brilinta | Ticagrelor | 118 | 36 |
| Azithromycin | Azithromycin | 117 | 91 |
| Warfarin Sodium | Warfarin Sodium | 117 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 55 |
| Vascepa | Icosapent Ethyl | 110 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 39 |
| Valsartan | Valsartan | 106 | 31 |
| Xarelto | Rivaroxaban | 105 | 19 |
| Donepezil Hcl | Donepezil Hcl | 104 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 49 |
| Amiodarone Hcl | Amiodarone Hcl | 102 | 31 |
| Famotidine | Famotidine | 101 | 38 |
| Nifedipine Er | Nifedipine | 101 | 34 |
| Januvia | Sitagliptin Phosphate | 94 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 93 | 35 |
| Nitroglycerin | Nitroglycerin | 92 | 38 |
| Diltiazem Hcl | Diltiazem Hcl | 90 | 22 |
| Labetalol Hcl | Labetalol Hcl | 90 | 27 |
| Mounjaro | Tirzepatide | 90 | 20 |
| Sucralfate | Sucralfate | 89 | 26 |
| Tradjenta | Linagliptin | 87 | 16 |
| Verquvo | Vericiguat | 87 | 25 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 83 | 31 |
| Promethazine Hcl | Promethazine Hcl | 81 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 51 |
| Glimepiride | Glimepiride | 77 | 22 |
| Tramadol Hcl | Tramadol Hcl | 77 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 23 |
| Prednisone | Prednisone | 75 | 25 |
| Alendronate Sodium | Alendronate Sodium | 74 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 26 |
| Naproxen | Naproxen | 68 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 17 |
| Cilostazol | Cilostazol | 65 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 20 |
| Sertraline Hcl | Sertraline Hcl | 64 | 13 |
| Ibuprofen | Ibuprofen | 63 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 22 |
| Ranolazine Er | Ranolazine | 62 | 15 |
| Digoxin | Digoxin | 61 | 12 |
| Latanoprost | Latanoprost | 61 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 17 |
| Methylprednisolone | Methylprednisolone | 60 | 47 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 59 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 11 |
| Finasteride | Finasteride | 58 | 15 |
| Trulicity | Dulaglutide | 58 | 15 |
| Lactulose | Lactulose | 57 | 23 |
| Midodrine Hcl | Midodrine Hcl | 56 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 55 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 24 |
| Colchicine | Colchicine | 52 | 16 |
| Mirtazapine | Mirtazapine | 52 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 12 |
| Mometasone Furoate | Mometasone Furoate | 48 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 15 |
| Insulin Lispro | Insulin Lispro | 47 | 19 |
| Prasugrel Hcl | Prasugrel Hcl | 47 | 14 |
| Chlorthalidone | Chlorthalidone | 46 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 13 |
| Ammonium Lactate | Ammonium Lactate | 43 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | 17 |
| Baclofen | Baclofen | 41 | suppressed |
| Glipizide | Glipizide | 40 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 14 |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 40 | 14 |
| Alprazolam | Alprazolam | 39 | 19 |
| Meclizine Hcl | Meclizine Hcl | 39 | 17 |
| Metolazone | Metolazone | 39 | 17 |
| Lorazepam | Lorazepam | 38 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Linzess | Linaclotide | 37 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | 15 |
| Metformin Hcl Er | Metformin Hcl | 36 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 34 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 34 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 21 |
| Lidocaine | Lidocaine | 32 | 13 |
| Memantine Hcl | Memantine Hcl | 32 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 15 |
| Amoxicillin | Amoxicillin | 31 | 17 |
| Enoxaparin Sodium | Enoxaparin Sodium | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | 18 |
| Meloxicam | Meloxicam | 31 | 17 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | 11 |
| Nystatin | Nystatin | 29 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Scopolamine | Scopolamine | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 13 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | 19 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 19 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Fluconazole | Fluconazole | 16 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Telmisartan | Telmisartan | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | 12 |
| Primidone | Primidone | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,279.18 · 82 records | Abbott Laboratories | AIRSUPRA, AVEIR, Attruby, CAMZYOS, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FARXIGA, FFRct, INGREZZA, JARDIANCE, Kerendia, LEQVIO, LifeVest, MOUNJARO, Omnipod, Ozempic, PRECIVITYAD2, Rybelsus, VALTOCO, VERQUVO, VYNDAQEL, VYVGART HYTRULO, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error